• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    11/14/24 8:35:56 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email
    SC 13G/A 1 d815643dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c)

    AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    (Amendment No. 5)*

     

     

    Replimune Group, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    76029N106

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 76029N106    13G    Page 2 of 9

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund IV, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,709,991

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,709,991

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,709,991

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.0% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Francesco Draetta (“Draetta”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    CUSIP NO. 76029N106    13G    Page 3 of 9

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund IV GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,709,991

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,709,991

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,709,991

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.0% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Francesco Draetta (“Draetta”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    CUSIP NO. 76029N106    13G    Page 4 of 9

     

     1   

     NAMES OF REPORTING PERSONS

     

     Omega Fund IV GP Manager, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,709,991

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,709,991

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,709,991

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.0% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Francesco Draetta (“Draetta”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    CUSIP NO. 76029N106    13G    Page 5 of 9

     

     1   

     NAMES OF REPORTING PERSONS

     

     Otello Stampacchia

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Italy

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,709,991

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,709,991

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,709,991

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.0% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Francesco Draetta (“Draetta”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    CUSIP NO. 76029N106    13G    Page 6 of 9

     

     1   

     NAMES OF REPORTING PERSONS

     

     Francesco Draetta

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒ (1)

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     2,709,991

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     2,709,991

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,709,991

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     4.0% (2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    This Schedule 13G is filed by Omega Fund IV, L.P. (“Omega Fund”), Omega Fund IV GP, L.P. (“Omega GP”), Omega Fund IV GP Manager, Ltd. (“Omega Ltd”), Otello Stampacchia (“Stampacchia”), and Francesco Draetta (“Draetta”) (together, the “Reporting Persons”). Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund; and each of Omega Ltd and Omega GP may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund. The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    CUSIP NO. 76029N106    13G    Page 7 of 9

     

    Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”), of Replimune Group, Inc. (the “Issuer”).

    Item 1(a) Name of Issuer:

    Replimune Group, Inc. (the “Issuer”)

    Item 1(b) Address of Issuer’s principal executive offices:

    Replimune Group, Inc.

    500 Unicorn Park

    Woburn, MA 01801

    Items 2(a) Name of Reporting Persons filing:

    Omega Fund IV, L.P. (“Omega Fund”)

    Omega Fund IV GP, L.P. (“Omega GP”)

    Omega Fund IV GP Manager, Ltd. (“Omega Ltd.”)

    Otello Stampacchia (“Stampacchia”)

    Francesco Draetta (“Draetta”)

    Item 2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Stampacchia and Draetta is c/o Omega Fund Management, LLC, 888 Boylston Street, Suite 1111, Boston, MA 02199.

    Item 2(c) Citizenship:

     

    Name    Citizenship or Place of Organization
    Omega Fund    Cayman Islands
    Omega GP    Cayman Islands
    Omega Ltd.    Cayman Islands
    Stampacchia    Italy
    Draetta    United States

    Item 2(d) Title of class of securities:

    Common Stock

    Item 2(e) CUSIP No.:

    76029N106

    Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

    Not applicable.

    Item 4 Ownership

    The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of September 30, 2024.

     

    Reporting Persons    Shares of
    Common
    Stock Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class
    (1)
     

    Omega Fund(2)(3)

         2,709,991        0        2,709,991        0        2,709,991        2,709,991        4.0 % 

    Omega GP(2)(3)

         0        0        2,709,991        0        2,709,991        2,709,991        4.0 % 

    Omega Ltd(2)(3)

         0        0        2,709,991        0        2,709,991        2,709,991        4.0 % 

    Stampacchia(2)(3)

         0        0        2,709,991        0        2,709,991        2,709,991        4.0 % 

    Draetta(2)(3)

         0        0        2,709,991        0        2,709,991        2,709,991        4.0 % 

     

    (1)

    The following percentages are based on (i) 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission by the Issuer on August 8, 2024 and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock held by Omega Fund.


    (2)

    Omega Fund owns (i) 2,461,319 shares of Common Stock and (ii) immediately exercisable warrants to purchase 248,672 shares of Common Stock. Omega Ltd serves as the general partner of Omega GP, which serves as the general partner of Omega Fund, and each of Omega GP and Omega Ltd may be deemed to own beneficially the shares held by Omega Fund. Stampacchia and Draetta are the directors of Omega Ltd and may be deemed to beneficially own the shares held by Omega Fund.

    (3)

    The Reporting Persons may be deemed a “group” for purposes of Section 13 of the Exchange Act and expressly disclaim status as a “group” for purposes of this Schedule 13G.

    Item 5 Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

    Item 6 Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not applicable.

    Item 8 Identification and Classification of Members of the Group

    Not applicable.

    Item 9 Notice of Dissolution of Group

    Not applicable.

    Item 10 Certifications

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    OMEGA FUND IV, L.P.
    BY:   Omega Fund IV GP, L.P.
    ITS:   GENERAL PARTNER
    BY:   Omega Fund IV GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:  

    /s/ Otello Stampacchia

      Director
    OMEGA FUND IV GP, L.P.
    BY:   Omega Fund IV GP Manager, Ltd.
    ITS:   GENERAL PARTNER
    By:  

    /s/ Otello Stampacchia

      Director
    OMEGA FUND IV GP MANAGER, LTD.
    By:  

    /s/ Otello Stampacchia

      Director

    /s/ Otello Stampacchia

    Otello Stampacchia

    /s/ Francesco Draetta

    Francesco Draetta
    Get the next $REPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    8/28/2024$17.00Buy
    ROTH MKM
    4/17/2023$44.00Overweight
    Piper Sandler
    11/19/2021$52.00Overweight
    Piper Sandler
    10/15/2021$60.00Buy
    BTIG Research
    8/23/2021$55.00 → $49.00Outperform
    SVB Leerink
    8/9/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      - RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. "The new analyses we pres

      6/1/25 10:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune to Present at the 2025 Jefferies Global Healthcare Conference

      WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th

      5/29/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

      •  BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete •  Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date •  Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update. "As we near our PDUFA date, our commercial organization is now fully hired and ready to execute our fir

      5/22/25 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Financials

    Live finance-specific insights

    See more
    • Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

      WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

      5/16/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

      Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

      6/6/24 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

      RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

      12/5/23 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    SEC Filings

    See more
    • SEC Form S-3 filed by Replimune Group Inc.

      S-3 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:34:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Replimune Group Inc.

      S-3 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:30:37 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Replimune Group Inc.

      S-8 - Replimune Group, Inc. (0001737953) (Filer)

      5/22/25 9:23:59 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

      Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

      3/26/24 7:30:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tessellate BIO Emerges from Stealth

      The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

      10/17/23 3:00:00 AM ET
      $NAMS
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Replimune with a new price target

      ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00

      8/28/24 7:52:10 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler resumed coverage on Replimune with a new price target

      Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00

      4/17/23 7:34:30 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Replimune Group with a new price target

      Piper Sandler initiated coverage of Replimune Group with a rating of Overweight and set a new price target of $52.00

      11/19/21 6:41:32 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Astley-Sparke Philip sold $260,169 worth of shares (32,279 units at $8.06), decreasing direct ownership by 2% to 1,405,071 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:47:07 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Xynos Konstantinos sold $64,093 worth of shares (7,952 units at $8.06), decreasing direct ownership by 5% to 146,933 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:46:09 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Schwendenman Andrew sold $26,460 worth of shares (3,287 units at $8.05), decreasing direct ownership by 5% to 68,284 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:45:30 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 4:20:10 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 1:22:38 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 8:35:56 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care